country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-177893

Copy Link Print Information

OZD-MET 01

OZD-MET 01 is a chaperone-based PROTAC-class MET protein degrader. OZD-MET 01 induces MET protein degradation in lung cancer cells in a time- and dose-dependent manner and inhibits cancer cell proliferation. OZD-MET 01 can be used in studies related to non-small cell lung cancer.
(Pink: c-Met/HGFR ligand (HY-50878); Blue: HSP90 ligand (HY-176951); Black: linker (HY-176952)).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 3048497-38-4
Formel: C₄₅H₅₀Cl₂FN₇O₈
Molecular Weight:906.83

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (274 KB)

OZD-MET 01 Chemical Structure

CAS. Nr.: 3048497-38-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

OZD-MET 01 is a chaperone-based PROTAC-class MET protein degrader. OZD-MET 01 induces MET protein degradation in lung cancer cells in a time- and dose-dependent manner and inhibits cancer cell proliferation. OZD-MET 01 can be used in studies related to non-small cell lung cancer^[1]. (Pink: c-Met/HGFR ligand (HY-50878); Blue: HSP90 ligand (HY-176951); Black: linker (HY-176952)).

Alle PROTACs Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
NCI-H596	IC50	3.07 μM	Inhibition of H596 cell viability assessed via CCK8 assay following 3-day treatment with OZD-MET 01, with absorbance measured at 450 nM using an ELISA reader. Inhibition of H596 cell viability assessed via CCK8 assay following 3-day treatment with OZD-MET 01, with absorbance measured at 450 nM using an ELISA reader.	en?oq=WO2024144088
NCI-H1437	IC50	3.50 μM	Inhibition of H1437 cell viability assessed via CCK8 assay following 3-day treatment with OZD-MET 01, with absorbance measured at 450 nM using an ELISA reader. Inhibition of H1437 cell viability assessed via CCK8 assay following 3-day treatment with OZD-MET 01, with absorbance measured at 450 nM using an ELISA reader.	en?oq=WO2024144088

In Vitro

OZD-MET 01 (administered consecutively for 3 days) potently inhibits the viability of H596 and H1437 cells, with IC₅₀ values of 3.07 μM and 3.50 μM, respectively^[1].
OZD-MET 01 (2.5-10 μM; 6-72 h) induces more than 50% degradation of c-MET protein in H596 and H1437 cells^[1].
OZD-MET 01 (5 μM; 16 h, co-treated with 100 nM proteasome inhibitor Bortezomib (HY-10227)) mediates UPS-dependent c-MET degradation in H596 and H1437 cells, and the recovery rate of c-MET expression exceeds 50% after co-treatment with the proteasome inhibitor Bortezomib^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

H596 cells; H1437 cells
Concentration:

2.5, 5 and 10 μM; 5 μM (standard condition)
Incubation Time:

6, 8, 24, 48, 72 h; 72 h (standard condition)
Result:

Induced greater than 50% degradation of c-MET protein in H596 and H1437 cells.

Western Blot Analysis^[1]

Cell Line:

H596 cells; H1437 cells
Concentration:

5 μM (co-treated with 100 nM proteasome inhibitor Bortezomib (HY-10227))
Incubation Time:

16 h
Result:

Mediated c-MET degradation in H596 and H1437 cells that was reversed with >50% recovery when co-treated with the proteasome inhibitor Bortezomib.

Related Protocols :

Chemical Information

CAS. Nr. 3048497-38-4
Molecular Weight 906.83
Formel C₄₅H₅₀Cl₂FN₇O₈
SMILES

C[C@@H](OC1=CC(C2=CN(N=C2)C3CCN(C(OCCOCCNC(C4=CC(CN(C(C5=CC(C(C)C)=C(O)C=C5O)=O)C)=CC=C4)=O)=O)CC3)=CN=C1N)C6=C(Cl)C(F)=CC=C6Cl
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (274 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Joo-hoon AHN, et al. Met protein degradation inducing compound. WO2024144088A1. 2025-06-27

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen